source
- Alnylam shares tumble 25% as analysts flag uncertainties in its transthyretin franchiseAlnylam Therapeutics saw its stock fall about a quarter on Thursday, closing near $174 after analysts highlighted a trio of uncertainties surrounding its transthyretin (TTR) franchise. The TTR fra…
- Early-stage data show promise for targeting Wnt/β-catenin pathway across cancersEarly-stage clinical results from the company and several peers indicate that the Wnt/β-catenin signaling pathway could become a viable target for treating a range of tumor types. The pathway has…